Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis

被引：0
|
作者：
Ahmad, Suhana [1 ]
Lambuk, Lidawani [1 ]
Ahmed, Naveed [2 ]
Mussa, Ali [3 ,4 ]
Tee, Vincent [5 ]
Idris, Ros Akmal Mohd [1 ]
Sahran, Nur Fazimah [5 ]
Chan, Yean Yean [2 ]
Hassan, Rosline [3 ]
Lee, Yeong Yeh [5 ,6 ]
Mohamud, Rohimah [1 ]
机构：
[1] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian 16150, Kelantan, Malaysia
[2] Univ Sains Malaysia, Sch Med Sci, Dept Med Microbiol & Parasitol, Kubang Kerian 16150, Kelantan, Malaysia
[3] Univ Sains Malaysia, Sch Med Sci, Dept Haematol, Kubang Kerian 16150, Kelantan, Malaysia
[4] Omdurman Islamic Univ, Dept Biol, Omdurman 14415, Sudan
[5] Univ Sains Malaysia, Sch Med Sci, Dept Internal Med, Kubang Kerian 16150, Kelantan, Malaysia
[6] Univ Sains Malaysia, Hosp Univ Sains Malaysia, GI Funct & Motil Unit, Kubang Kerian 16150, Kelantan, Malaysia
来源：
NANOMEDICINE | 2023年 / 18卷 / 24期
关键词：
chemotherapy; nanomedicine; nanoparticle; response rate survival; ALBUMIN-BOUND PACLITAXEL; SOLVENT-BASED PACLITAXEL; PHASE-II; CHEMOTHERAPY; RAMUCIRUMAB; COMBINATION;
D O I：
10.2217/nnm-2022-0300
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Background: Nab-paclitaxel is formulated to address several limitations of paclitaxel. Methods: A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab-paclitaxel in metastatic gastric cancer (MGC). Results: Included studies revealed that nab-paclitaxel provides a 30.4% overall response rate and 65.7% disease control rate in MGC patients. The overall survival was 9.65 months and progression-free survival was 4.48 months, associated with the treatment line and regimen. The highest incidence of grade 3 and higher treatment-related adverse events was for neutropenia (29.9%). Conclusion: Nab-paclitaxel provides better disease response and longer survival with manageable side effects in MGC compared with paclitaxel. A systematic review and meta-analysis estimates the efficacy and safety of nab-paclitaxel in metastatic gastric cancer.
引用
收藏
页码：1733 / 1744
页数：12
相关论文
共 50 条
  • [41] Safety and Efficacy of Gemcitabine Plus Nab-Paclitaxel for Metastatic Pancreatic Cancer Patients Undergoing Biliary Stent Placement
    Inoue, Tadahisa
    Ibusuki, Mayu
    Kitano, Rena
    Sakamoto, Kazumasa
    Kimoto, Satoshi
    Kobayashi, Yuji
    Ohashi, Tomohiko
    Sumida, Yoshio
    Nakade, Yukiomi
    Ito, Kiyoaki
    Yoneda, Masashi
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (07) : 3298 - 3304
  • [42] Retrospective Analysis of Efficacy and Safety in Chinese Elderly Patients Treated with Nab-Paclitaxel
    Wang, S.
    Ping, Q.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S906 - S906
  • [43] Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life
    De Luca, Rossella
    Profita, Giuseppe
    Cicero, Giuseppe
    ONCOTARGETS AND THERAPY, 2019, 12 : 1621 - 1627
  • [44] Nab-paclitaxel in patients with metastatic melanoma
    Leon-Ferre, Roberto A.
    Markovic, Svetomir N.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (12) : 1371 - 1377
  • [45] Efficacy of Nab-Paclitaxel Does Not Seem to Be Associated with SPARC Expression in Metastatic Breast Cancer
    Schneeweiss, Andreas
    Seitz, Julia
    Smetanay, Katharina
    Schuetz, Florian
    Jaeger, Dirk
    Bachinger, Andreas
    Zorn, Markus
    Sinn, Hans-Peter
    Marme, Frederik
    ANTICANCER RESEARCH, 2014, 34 (11) : 6609 - 6615
  • [46] The comparison of the usefulness of nab-paclitaxel and paclitaxel for advanced or recurrent gastric cancer
    Kimura, Yasue
    Kusumoto, Tetsuya
    Kusumoto, Eiji
    Sugiyama, Masahiko
    Ohta, Mitsuhiko
    Tsutsumi, Norifumi
    Sakaguchi, Yoshihisa
    Ikejiri, Koji
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [47] Nab-paclitaxel utilization pattern and safety profile in patients with metastatic breast and pancreatic cancer
    Cortes de Miguel, S.
    Ruiz Fuentes, S.
    Belda Rustarazo, S.
    Valle Corpas, M.
    Casas Hidalgo, I.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 507 - 507
  • [48] Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis
    Li, Yong
    Lu, Xiaoju
    Lin, Qimou
    Li, Weiwen
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (08)
  • [49] Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
    Fukuchi, Minoru
    Mochiki, Erito
    Ishiguro, Toru
    Ogura, Toshiro
    Sobajima, Jun
    Kumagai, Youichi
    Ishibashi, Keiichiro
    Ishida, Hideyuki
    ANTICANCER RESEARCH, 2016, 36 (12) : 6699 - 6703
  • [50] Efficacy of pembrolizumab versus paclitaxel for gastric cancer: meta-analysis
    Albert, N.
    Sabran, M. Zuhriansyah
    Mokalu, E. Wilhelmina
    Zebua, A.
    Rubismo, K. Yogasvara
    Kurniawan, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1369 - S1369
12345